Category: CureVac

Pfizer, BioNTech Seek to Revoke CureVac’s Patent Infringement Claims

September 5, 2022
Business & MarketsBusinesses in COVID-19COVID-19CureVacPfizer
0 Comment

Pfizer and its German partner BioNTech have filed proceedings at the High Court of England and Wales, seeking a judgment that their COVID-19 vaccine, based on mRNA technology, does not infringe on CureVac’s European patents, according to a regulatory filing on Friday. In July, CureVac had filed a patent lawsuit against BioNTech over its use…

Read More

BioNTech, Pfizer Sue CureVac in US Over COVID-19 Vaccine Patent Claims

July 28, 2022
BioNTechBusiness & MarketsBusinesses in COVID-19CCP VirusCompaniesCureVaceconomyPfizerVaccines & Safety
0 Comment

FRANKFURT—COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer’s COVID-19…

Read More

CureVac Files Patent Lawsuit in Germany Against BioNTech

July 6, 2022
BioNTechBusiness & MarketsCompaniesCOVID-19 vaccineCureVac
0 Comment

BERLIN—CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus. The German-based biotech company is seeking “fair compensation” from BioNTech and two subsidiaries for infringement…

Read More

CureVac COVID-19 Vaccine Records 48 Percent Efficacy in Final Trial Readout

July 1, 2021
CCP VirusCOVID-19 vaccineCureVacEuropeVaccines & SafetyWorld
0 Comment

CureVac said its COVID-19 vaccine was 48 percent effective in the final analysis of its pivotal mass trial, only marginally better than the 47 percent reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53 percent when excluding trial participants…

Read More